tbuckley/cabot-search huggingface dataset:
The impact of comorbidity on survival among men with localized prostate cancer.
Authors: G. L. Lu-Yao, D. Moore, W. Shih, Y. Lin, H. Li, P. C. Albertsen
Journal: Journal of Clinical Oncology (2011)

8 Background: To provide patients and clinicians more accurate estimates of co-morbidity specific survival stratified by patient age, tumor stage and tumor grade. Methods: We conducted a ten year competing risk analysis of 19,639 men age 66 years and older identified by the Surveillance, Epidemiology and End Results (SEER) program linked to Medicare program files. All men were diagnosed with localized prostate cancer and received no surgery or radiation within 180 days of diagnosis. The analysis was stratified by tumor grade and stage and by age and co-morbidity at diagnosis classified using the Charlson co-morbidity index. Underlying causes of death were obtained from SEER. Results: During the first ten years following diagnosis men with moderately and poorly differentiated prostate cancer were more likely to die from causes other than their disease. For men age 66-74 years with stage T1c Gleason score 5-7 disease at diagnosis, ten year overall mortality rates and prostate cancer specific rates were 28.8%, 50.5%, 83.1% and 4.8%, 2.0%, 5.3% respectively for men with Charlson scores 0, 1 and &gt; 2. For men age 66-74 years with T1c Gleason score 8-10 disease at diagnosis, the corresponding rates were 55.0%, 52.0%, 64.3% and 25.7%, 20.2%, 13.7% respectively for men with Charlson scores 0, 1, &gt; 2. Death from competing medical hazards was roughly comparable for men with stage T2 disease and higher for all men over age 75. Conclusions: Patients and clinicians should consider using co-morbidity specific data to estimate the threat posed by localized prostate cancer. No significant financial relationships to disclose.
Cocaine Kindling
Authors: George B. Murray
Journal: JAMA (1986)

<h3>To the Editor.—</h3> The recent cocainerelated deaths of two professional athletes have again emphasized that cocaine use can be life threatening.<sup>1</sup>Both athletes, according to the media, suffered a seizure prior to death. The possibility of a tonic-clonic seizure occurring as a result of cocaine use is well documented.<sup>2</sup> It is thought that cocaine produces its euphoric effect in limbic structures. Cocaine, like procaine, is a strong effector of kindling, which is more easily effected in the limbic system.<sup>3</sup>A complex partial seizure is often seen in partially kindled animals before a generalized seizure is seen as the end point of kindling. For kindling to take place, an intermittent stimulus is required; most cocaine users are intermittent users. More recently, complex partial seizures have been linked to cardiac dysfunction and arrest.<sup>4,5</sup>Since the amygdala is the limbic structure most vulnerable to kindling and since the amygdala
Heroic surgery
Authors: Martin Christie
Journal: BMJ (2004)

triage and had an interest in new methods of arranging appointments. ConclusionsWe have shown that external management of requests for same day appointments through NHS Direct is feasible but comes at a higher cost than practice nurse delivered triage.Outcomes for patients on the day of the request were more likely to involve an appointment with a general practitioner in the NHS Direct group.If NHS Direct could achieve the same patient disposal proportions as practice based triage, costs would be comparable.External triage of same day appointment requests is, therefore, possible, although no economies of scale are possible.Nonetheless, the flexibility of an organisation the size of NHS Direct could ensure coverage of all the triage needed.An external triage service might be feasible for smaller practices with fewer resources to organise their own systems.
Observational Study Suggests Hormone Therapy Safe for Postmenopausal BRCA Mutation Carriers
Authors: Rowan Chlebowski
Journal: JNCI Journal of the National Cancer Institute (2008)

Observational Study Suggests Hormone Therapy Safe for Postmenopausal BRCA Mutation CarriersThe use of hormone therapy was associated with a reduced risk of breast cancer in postmenopausal women who carry BRCA mutations, according to a case-control study published online September 23 in the Journal of the National Cancer Institute.Women who carry a mutation in the BRCA1 gene may opt to have their ovaries removed to lower their risk of developing breast cancer.The surgery, however, induces menopause, and thus some women opt to take hormone therapy to reduce its symptoms.The impact of hormone therapy on the risk of breast cancer is these women is not known.To fi nd out, Steven Narod, M.D., of the University of Toronto and colleagues compared the use of hormone therapy in 236 breast cancer patients and 236 matched control subjects.All of the study participants carried a mutation in BRCA1 .Narod and colleagues report that 68 (29%) of the control subjects had used hormone therapy at some time, as had 47 (20%) of the women in the breast cancer group.The use of hormone therapy was associated with a 42% relative reduction in the risk of developing breast cancer.The researchers did not fi nd a difference in risk reduction associated with estrogen-only or estrogen-progesterone therapies, however the reduction did not reach statistical signifi cance in the estrogen-progesterone subgroup.The researchers did not detect a difference in risk reduction between women who had undergone natural, age-related menopause and those who had undergone surgically induced menopause."The magnitude of the association appeared to be as great, or even greater, for women after surgical menopause than it was for women after natural menopause.This information should be reassuring to women who wish to undergo preventive oophorectomy before menopause, but it needs to be confi rmed in subsequent studies," the authors write.
Seven days in medicine: 20-27 February
Journal: BMJ (2016)

20-27 February NHS finance NHS overspend reaches £2.3bnThe NHS in England overspent by £2.26bn (€2.9bn; $3.2bn) in the first three quarters of this financial year (April to December 2015), figures from the healthcare regulator Monitor and the NHS Trust Development Authority show, and the overspend is forecast to reach £2.37bn by the end of March.Three quarters of providers are in deficit, including 132 acute care trusts.The regulators blamed use of agency staff, delayed transfers of care, and "failure to deliver the level of cost improvement schemes planned at the start of the year.
Screening test for Cushing's syndrome with plasma 11-hydroxycorticosteroids
Authors: J. F. Seidensticker
Journal: JAMA (1967)

In a rapid screening test for Cushing's syndrome, plasma cortisol was measured by a simple fluorometric method. We have verified the value of the overnight suppression test as a screening test for hyperadrenocorticism. An 8 AM plasma cortisol level of less than 10μg/ 100 ml after a single dose of 1 mg of dexamethasone was given orally the previous night at 11 PM essentially rules out Cushing's syndrome. Emotional or psychiatric disorders and acute illnesses may result in incomplete suppression. Oral contraceptive agents do not ordinarily result in a false-positive test. Patients who do not respond normally to overnight suppression with dexamethasone warrant further study.
Gastrin, a Stimulant of Pepsin Secretion
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Military Nursing
Authors: Brigid Lusk
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Serum Vitellogenin Levels and Reproductive Impairment of Male Japanese Medaka (Oryzias latipes) Exposed to 4-tert-Octylphenol
Authors: Suzanne Gronen, Nancy Denslow, Steve Manning, Sue Barnes, David Barnes, Marius Brouwer
Journal: Environmental Health Perspectives (1999)

The induction of synthesis of the "female" yolk precursor protein vitellogenin (VTG) in male fish by estrogenic chemicals in the environment has been demonstrated in many recent reports. However, little is known about the organismal and biological significance of this phenomenon. To examine the relationship between VTG production in male fish and reproductive impairment, adult male medaka were exposed to 4-tert-octylphenol (OP), a known environmental estrogen, in concentrations ranging from 20 to 230 ppb for 21 days, under flow-through conditions. Following exposure, male fish were mated, in the absence of OP, with unexposed females. Breeding groups composed of exposed males and control females produced about 50% fewer eggs than control groups. VTG levels in serum of male fish increased with increasing OP exposure concentration and decreased after OP exposure was discontinued. Nevertheless, significant correlations (p<0.01) were observed between VTG levels in exposed male fish and 1) OP exposure concentrations, 2) percent of fertilized eggs, and 3) survival of embryos. OP-induced VTG synthesis and reproductive impairment appear to be closely linked phenomena. Histological examination indicated spermatogenesis in OP-exposed fish was inhibited, and some exposed fish had oocytes in their testes. Finally, OP caused a significant increase in the number of abnormally developing embryos, suggesting that OP may be genotoxic as well as estrogenic.
PDCT-04. SAFETY AND EFFICACY OF INTRAVENTRICULAR 131I-LABELED MONOCLONAL ANTIBODY 8H9 TARGETING THE SURFACE GLYCOPROTEIN B7-H3 IN PATIENTS WITH CNS/LM DISEASE
Authors: Kim Kramer, Brian Kushner, Shakeel Modak, Neeta Pandit-Taskar, Ursula Tomlinson, Maria Donzelli, Suzanne Wolden, Pat Zanzonico, John Humm, Sophia Haque, Mark Souweidane, Jeffrey Greenfield, Ellen Basu, Stephen Roberts, Jorge Carrasquillo, Jason Lewis, Serge Lyashchenko, Steven Larson, Nai-Kong Cheung
Journal: Neuro-Oncology (2017)

Tumors metastasizing to the central nervous system (CNS) are associated with significant mortality. Intraventricular 131I-labeled monoclonal antibody targeting tumor associated antigens may eradicate micrometastases. We tested the toxicity and dosimetry of intraventricular 131I-labeled monoclonal antibody 8H9 targeting surface glycoprotein B7-H3 in patients with CNS disease on a phase I/II trial. Adequate CSF flow was determined by 111Indium-DTPA cisternography through intraventricular devices. 131 patients [median age 5.4 years (1.2- 53.6 years)] with primary CNS malignancies or malignancies metastatic to the CNS received 383 injections involving 2 mCi 124I- or 131I-8H9 as a tracer for nuclear imaging and a therapeutic injection (10-80 mCi, dose levels 1-8 in 10 mCi increments for phase I patients; expanded cohort 50 mCi/injection) 131I-8H9. Pharmacokinetics were studied by serial CSF and blood samplings over 48 hours. Dosimetry was based on pharmacokinetics and ROI analyses on serial scans. Toxicity was defined by CTCAE v3.0. Injections were repeated after 1 month in the absence of serious adverse event or progressive disease. Tumor response was determined by clinical, radiographic, cytologic criteria; overall survival was noted. Injections were well tolerated and routinely administered in the outpatient setting. Rare self-limited adverse events included grade 1 or 2 fever, headache, vomiting, biochemical elevations in AST or ALT [1 injection with grade 3 ALT elevation (dose level 3)]. Although not a dose limiting toxicity, myelosuppression was observed in patients who had received craniospinal radiation. Mean absorbed CSF dose was 104.9 cGy/mCi and 2.6 cGy/mCi to the blood. Of 93 patients treated for metastatic CNS neuroblastoma, an improved overall survival was noted compared to median survival reported with conventional therapies. Intraventricular 131I-8H9 is safe, has favorable CSF and blood dosimetry, and has clinical utility in the treatment of B7-H3 -positive CNS cancers.
Yale Journal of Biology and Medicine, New Haven
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leads from the MMWR. Suboptimal response to hepatitis B vaccine given by injection into the buttock
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Breakthrough during therapy with natural interferons alpha for chronic hepatitis C Internal Medicine Niguarda Hospital, Milan; *Chair Internal Medicine, S.Gerardo Hospital, Monza (MI); ?Inst. of Virology, University of Pisa, Pisa; ?Chair Internal Medicine, Bolognini Hospital, Seriate (BG); IInstitute of Virology, University of Rome, Rome; UMagenta Hospital, Magenta (MI); **Internal Medicine Mestre Hospital (VE); ? Chronic Hepatitis Study Group; Italy
Journal: Hepatology (1995)
Systematic examination of the influence of carbohydrate supplementation on physical and mental performance in cool conditions
Authors: P Watson, D Ferguson, A Ewington, R J Maughan
Journal: British Journal of Sports Medicine (2010)

Most commercially available sports drinks contain 6%-8% carbohydrate (CHO). The present study systematically evaluated the effects of lower concentrations of CHO on physical and mental performance. Twelve healthy males (mean±SD age 22±2 years; height 181±8 cm; mass 73.5±8.1 kg; VO 2max 4.0±0.5 l/min) exercised to volitional exhaustion at a workload corresponding to 70% VO 2max at 10°C, 60% RH. Subjects ingested 3 ml/kg body mass of a 0%, 2%, 4% or 6% CHO solution immediately before exercise and a further 1.5 ml/kg body mass of the appropriate solution every 10 min during exercise. Heart rate, core temperature, perceived exertion and thermal stress were recorded at regular intervals. Expired gas samples were collected to determine rates of substrate utilisation. Cognitive function was assessed using a computerised test battery. Exercise time to exhaustion was 102.6±33.9 min, 109.2±33.9 min, 121.0±25.7 min and 122.4±29.9 min in the 0%, 2%, 4% and 6% trials, respectively (p=0.012). Drink CHO content did not influence heart rate (p=0.261) or core temperature (p=0.545). Rates of CHO (p=0.244) and fat (p=0.136) oxidation were not influenced by the treatment, but total CHO utilisation was greater during the 4% (454±125 g) and 6% (441±118 g) trials than on the 0% (325±105 g) and 2% (364±106 g; p=0.001). Exercise resulted in a slowing of response times to a visual search task in all trials (p=0.006). This response appeared to be attenuated by CHO ingestion during the complex/interference level, but this just failed to reach significance (p&gt;0.05). The present study demonstrated a progressive increase in endurance performance with increasing CHO concentration. There was some suggestion that CHO may also attenuate decrements in motor skills tasks performed after exhausting exercise. The study was carried out in relation to the product Powerade and was funded in part by The Coca-Cola Company.
Methodologic Error Affecting Study Results
Authors: Theodore Satterthwaite, Raquel Gur
Journal: JAMA Psychiatry (2017)

Theodore D. Satterthwaite, MD, MA; Daniel H. Wolf, MD, PhD; Monica E. Calkins, PhD; Simon N. Vandekar, BS; Guray Erus, PhD; Kosha Ruparel, MS; David R. Roalf, PhD; Kristin A. Linn, PhD; Mark A. Elliott, PhD; Tyler M. Moore, PhD; Hakon Hakonarson, MD, PhD; Russell T. Shinohara, PhD; Christos Davatzikos, PhD; Ruben C. Gur, PhD; Raquel E. Gur, MD, PhD
Production of Functional Classical Brown Adipocytes from Human Pluripotent Stem Cells using Specific Hemopoietin Cocktail without Gene Transfer
Authors: Miwako Nishio, Takeshi Yoneshiro, Masako Nakahara, Shinnosuke Suzuki, Koichi Saeki, Mamoru Hasegawa, Yuko Kawai, Hidenori Akutsu, Akihiro Umezawa, Kazuki Yasuda, Kazuyuki Tobe, Akira You, Kazuo Kubota, Masayuki Saito, Kumiko Saeki
Journal: Cell Metabolism (2012)
Studies of drug usage in five Boston hospitals
Authors: I. Borda
Journal: JAMA (1967)

A study of drug usage was conducted in five hospitals: two hospitals for patients with acute diseases, two for patients requiring long-term care, and one pediatric hospital. Partially due to the increased length of hospitalization, more drugs were used in long-term hospitals. The number of different drugs used to treat the same problem varied greatly. For some therapeutic indications, one particular drug was widely accepted by most hospitals; in others, there was a wide variance. More than one drug of the same pharmacological action was often prescribed for the same patient. Older patients and women received more drugs. Antibiotics were used in a high percentage of all hospital patients. There were many incomplete prescriptions and discrepancies between drug orders written by doctors and records of medications administered by nurses. These results indicate the need for an epidemiologic approach to therapeutics.
Der Rheumatismus: Sammlung von Einzeldarstellungen aus dem Gesamtgebeit der Rheumaerkrankungen
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Human monitors for carbon monoxide levels
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal